Zacks Investment Research upgraded shares of NuCana (NASDAQ:NCNA) from a hold rating to a buy rating in a research note published on Saturday, Zacks.com reports. Zacks Investment Research currently has $11.00 target price on the stock.
According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “
A number of other analysts have also recently commented on NCNA. William Blair reiterated an outperform rating on shares of NuCana in a research report on Thursday, May 16th. ValuEngine upgraded NuCana from a hold rating to a buy rating in a research report on Thursday, August 1st. Finally, BidaskClub upgraded NuCana from a strong sell rating to a sell rating in a research report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of $23.50.
NuCana (NASDAQ:NCNA) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.22) EPS for the quarter, hitting analysts’ consensus estimates of ($0.22). Equities analysts expect that NuCana will post -1.14 EPS for the current fiscal year.
Large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC acquired a new stake in NuCana in the 2nd quarter worth about $32,000. Aperio Group LLC acquired a new stake in NuCana in the 2nd quarter worth about $39,000. Rothschild Investment Corp IL acquired a new stake in NuCana in the 1st quarter worth about $211,000. Asymmetry Capital Management L.P. boosted its stake in NuCana by 5.4% in the 1st quarter. Asymmetry Capital Management L.P. now owns 45,393 shares of the company’s stock worth $772,000 after buying an additional 2,346 shares during the last quarter. Finally, Marshall Wace North America L.P. boosted its stake in NuCana by 558.8% in the 1st quarter. Marshall Wace North America L.P. now owns 60,843 shares of the company’s stock worth $1,034,000 after buying an additional 51,607 shares during the last quarter. 38.09% of the stock is currently owned by hedge funds and other institutional investors.
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer.
Read More: What is a capital gains distribution?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.